Key facts
- This page summarizes Paul McCormac's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Nov 2023, 20:35.
Paul McCormac - 07 Nov 2023 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)
- Reporting relationship
- Chief Technical Officer
- Issuer ticker
- LXEO
- Reported as of
- 07 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Nov 2023, 20:35:09 UTC
- Prior SEC filing
- 02 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jenny Robertson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul McCormac filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 09 Nov 2023.
Change
- Previous filing in this sequence was filed on 02 Nov 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXEO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,191
- Change %
- +23%
- Price
- Shares after
- 17,349
- Date
- 07 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXEO
transaction
Derivative
Series B convertible preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -29,061
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,191
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.